Evidence map›Paper›PMID 38557574›Full record

ArticleJournal of water and health2024

Virucidal efficacy of hypochlorous acid water for aqueous phase and atomization against SARS-CoV-2.

Makoto Kubo, Ryotaro Eda, Shotaro Maehana, Hiroshi Fuketa, Norihiro Shinkai, Naohisa Kawamura, Hidero Kitasato, Hideaki Hanaki

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of water and health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Makoto KuboDepartment of Microbiology, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0373, Japan; Department of Environmental Microbiology, Kitasato University Graduate School of Medical Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0373, Japan; Research Facility of Regenerative Medicine and Cell Design, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0373, Japan E-mail: kuboma@kitasato-u.ac.jp.
Ryotaro EdaDepartment of Microbiology, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0373, Japan; Department of Environmental Microbiology, Kitasato University Graduate School of Medical Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0373, Japan; Research Facility of Regenerative Medicine and Cell Design, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0373, Japan.
Shotaro MaehanaDepartment of Microbiology, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0373, Japan; Department of Environmental Microbiology, Kitasato University Graduate School of Medical Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0373, Japan; Research Facility of Regenerative Medicine and Cell Design, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0373, Japan.
Hiroshi FuketaNIPRO Corporation, Pharmaceutical Research Laboratories, 7-2 Minamisakae-cho Kasukabe, Saitama 344-0057, Japan.
Norihiro ShinkaiNIPRO Corporation, Pharmaceutical Research Laboratories, 7-2 Minamisakae-cho Kasukabe, Saitama 344-0057, Japan.
Naohisa KawamuraNIPRO Corporation, Pharmaceutical Research Laboratories, 7-2 Minamisakae-cho Kasukabe, Saitama 344-0057, Japan.
Hidero KitasatoDepartment of Microbiology, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0373, Japan.
Hideaki HanakiInfection Control Research Center, The Omura Satoshi Memorial Institution, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.

Funding

Ministry of Health, Labour and Welfare 21HA2017
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) is an infectious viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged at the end of 2019. SARS-CoV-2 can be transmitted through droplets, aerosols, and fomites. Disinfectants such as alcohol, quaternary ammonium salts, and chlorine-releasing agents, including hypochlorous acid, are used to prevent the spread of SARS-CoV-2 infection. In the present study, we investigated the efficacy of ionless hypochlorous acid water (HOCl) in suspension and by spraying to inactivate SARS-CoV-2. The virucidal efficacy of HOCl solution in tests against SARS-CoV-2 was evaluated as 50% tissue culture infectious dose. Although the presence of organic compounds influenced the virucidal efficacy, HOCl treatment for 20 s was significantly effective to inactivate Wuhan and Delta strains in the suspension test. HOCl atomization for several hours significantly reduced the SARS-CoV-2 attached to plastic plates. These results indicate that HOCl solution with elimination containing NaCl and other ions may have high virucidal efficacy against SARS-CoV-2. This study provides important information about the virucidal efficacy and use of HOCl solution.

Indexed as

COVID-19DisinfectantsHumansHypochlorous AcidSARS-CoV-2WaterDisinfectantsHypochlorous AcidWateratomizationcoronavirus disease 2019 (COVID-19)hypochlorous acid water (HOCl)severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)suspension test

Identifiers

PMID38557574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.